Clinical trial · Interventional
Analysis of Circulating Tumor Markers in Blood - ALCINA 5
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to the mutational profile of the cancer), and could allow the study of the mechanisms of resistance under process. In the multiplicity of these blood potential biomarkers joins a permanent evolution of the technological means used to detect them/to quantify, as well as to estimate their clinical utility.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Lung Cancer, Non-Small Cell | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sampling C1 | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- COHORT 1 - CURE
- description
- Patients with histologically proven metastatic non-small cell lung carcinoma eligible for immunotherapy
- interventionNames
- Biological: Blood sampling C1
Primary outcomes (1)
- measure
- All Cohorts : Study of the feasibility of detecting and/or analysing blood or tissue tumour biomarkers.
- timeFrame
- 10 years
- description
- Success rate of the detection technique used (the criterion will be detailed according to the biomarker evaluated, in each of the cohorts)
Secondary outcomes (1)
- measure
- COHORT 1 - CURE : to define a liquid biopsy signature for predicting therapeutic response from samples taken before initiation of immunotherapy (T1).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patient presenting an invasive tumoral pathology (proved or suspected), whatever is the location or the stage, 2. 18 years old or higher ? 3. Patient who has provided informed, written, and explicit consent, 4. Patient affiliated with a French Social Protection System. In the case of a tumor biopsy: 5. Tumor considered as accessible by biopsy, 6. Normal hemostasis assessment (PT, APTT, platelets), 7. No anticoagulant or antiaggregant treatment for the biopsy. Exclusion Criteria: 1. Pregnant woman and/or breast-feeding, 2. Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons, 3. Private persons of freedom or under guardianship, 4. Patient with a history of other invasive cancers within the 5 years preceding inclusion.
References
Publications (0)
Data not yet available